Biognosys Expands with a US Office in Biopharma Hub Cambridge, Massachusetts

Biognosys Expands Its Global Presence with a US Office in Biopharma Hub Cambridge, Massachusetts

The expansion is part of the company’s growth strategy for North America and will foster collaboration with life science companies and academia


May 24, 2022. ZURICH and CAMBRIDGE, Mass. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they have opened an office in Cambridge, Massachusetts, a global hub of pharmaceutical and biotechnology companies.

The office opening is part of Biognosys’ ongoing expansion into North America and complements their expanding Business Development and Scientific teams located in the United States. The office will offer Biognosys employees in the US a place to work and meet and will facilitate meetings and project collaboration with US-based pharma and biotech companies.


The company plans for a grand inauguration event with collaborator presentations and networking opportunities later this year.

“The opening of a Biognosys office in Cambridge is a major milestone for Biognosys to expand our global footprint and grow our business in North America,” states Oliver Rinner, Ph.D., CEO and co-founder of Biognosys. “I am thrilled to now have a home to welcome our employees and collaborators right in the heart of this global biopharma hub.”

“Thanks to our Cambridge office, we will be closer than ever to our collaborators and customers to support their drug development efforts with our next-generation proteomics solutions,” comments Ben Gonzales, MBA, Head of Sales and Business Development, North America.

With its premium location right near Kendall Square, the Biognosys office is situated in the center of this global biopharma hub. For contact information, visit


About Biognosys


At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit


Media Contact Biognosys


Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21



Download PDF Version (English)

Back to News overview


Access our knowledge base with relevant resources and guiding information.


    Close banner

    SpectroDive™ 11

    Straightforward Validation
    of Your Protein Targets

    New: SpectroDive™ 11

    Straightforward Validation of Your Protein Targets

    learn more